MAGEC1 and cancer: Prominent CTA antigens like NY-ESO-1, LAGE-1, MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-C1 (CT-7) have demonstrated the potential to stimulate T-cell responses, making them candidates for cancer immunotherapy (38).